Skip to main content
. 2022 Aug 2;18(3):478–484. doi: 10.4103/1673-5374.350193

Figure 3.

Figure 3

Cell-based therapies trialed in patients and co-grafting strategies tested in animal models of PD.

The left-hand-side of the figure shows cell sources used in clinical trials in PD patients and the right-hand-side shows co-grafting strategies tested in animal models of PD. ESCs: Embryonic stem cells; fST: fetal striatal; fVM: fetal ventral mesencephalic; GDNF: glial cell line-derived neurotrophic factor; iPSCs: induced pluripotent stem cells; MSCs: mesenchymal stromal cells; NSCs: neural stem cells; OECs: olfactory ensheathing cells; PD: Parkinson’s disease. Created with BioRender (https://biorender.com/).